Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2024.09.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von HuiFang Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Liver Neoplasms, Colorectal Neoplasms, Contrast Media, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: We aimed to evaluate the role of Contrast-enhanced intraoperative ultrasound (CE-IOUS) with perfluorobutane microbubbles (Sonazoid) in improving the prognosis of patients with unresectable colorectal cancer liver metastases (CRLM). METHODS: A total of 130 Patients with unresectable CRLM who underwent curative hepatic resection at our institute were retrospectively analyzed. Of these 130 enrolled patients, 67 underwent intraoperative ultrasound alone (IOUS group); 63 underwent additional CE-IOUS and IOUS (CE-IOUS group). Normalized inverse probability treatment weighting (IPTW) was employed to balance baseline characteristics between groups. Hepatic recurrence-free survival (HRFS) and overall survival (OS) were compared. RESULTS: The treatment strategy was altered in 25 patients (25/63, 39.9%) due to the additional use of CE-IOUS. After applying IPTW, the CE-IOUS group exhibited a significantly lower rate of hepatic recurrence (hazard ratio [HR], 0.55; 95% confidence interval [CI] 0.32-0.95; P = 0.032). Subgroup analysis showed that CE-IOUS provided a significant benefit over IOUS in patients with bilobar liver metastases (P = 0.007), or with a number of live tumors < 3 (P = 0.021), or without DLM (P = 0.018), or with extrahepatic metastasis (P = 0.034), or with a minimum of 6 cycles of systemic therapy (P = 0.03). CONCLUSIONS: CE-IOUS is necessary for unresectable CRLM after preoperative chemotherapy, as it enhances detection accuracy and improves the prognosis of unresectable CRLM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China; Department of Liver Surgery, Sun Y…
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China; Department of Ultrasound, Sun Yat-…
- Department of Colorectal Surgery, the Sixth affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China; Department of Medical Oncology, Su…
Zitieren
APA
Li, H., Shi, M., Long, X., Huang, P., Peng, C., He, W., Li, Y., Li, B., Yuan, Y., Qiu, J., & Zou, R. (2025). Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.09.009
Vancouver
Li H, Shi M, Long X, Huang P, Peng C, He W, et al. Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.09.009
BibTeX
@article{Li2025,
author = {Li, HuiFang and Shi, Ming and Long, Xingzhang and Huang, Pinzhu and Peng, Chuan and He, Wei and Li, Yuhong and Li, Binkui and Yuan, Yunfei and Qiu, JiLiang and Zou, Ruhai},
title = {Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2024.09.009}
}
EUVIMED